Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
ARDX Transcript
Ardelyx, Inc. (ARDX) Q1 2026 Earnings Call Transcript
Positive4-30
The earnings call summary and Q&A session reveal strong financial performance, with a 32% increase in total dispenses and 19% in paid prescriptions, despite a market decline. Management's optimistic guidance, steady OpEx, and improved fulfillment rates support growth projections. The positive outlook for IBSRELA and XPHOZAH revenues, along with strategic investments, outweigh concerns about competition and enrollment pace. Given the market cap of $1.52 billion, these factors suggest a positive stock price movement of 2% to 8% over the next two weeks.
Ardelyx, Inc. (ARDX) Q4 2025 Earnings Call Transcript
Positive2-20
The earnings call reflects strong financial performance with raised revenue guidance for IBSRELA and growth expectations for XPHOZAH. The company is investing in pipeline development and commercial expansion, indicating confidence in future growth. While management avoided giving guidance on sustained cash flow positivity, they highlighted strategic investments and infrastructure sufficiency. The Q&A session reveals a focus on innovation and market expansion, with management addressing key concerns. Given the market cap of $1.52 billion, the positive guidance and strategic initiatives are likely to result in a positive stock price movement of 2% to 8% over the next two weeks.
Ardelyx, Inc. (ARDX) Q3 2025 Earnings Call Transcript
Positive10-30
The company's strong revenue guidance for IBSRELA and XPHOZAH, coupled with strategic market plans and financial flexibility, indicate positive momentum. The raised guidance for IBSRELA and the company's confidence in achieving sales targets for XPHOZAH are positive indicators. Despite a slight increase in net loss, cash reserves remain strong. The Q&A reveals confidence in market strategies and potential growth areas. The market cap suggests moderate volatility, leading to a positive prediction for stock price movement.
Ardelyx, Inc. (ARDX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Neutral9-8
ARDX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
